After stock slides, Amgen addresses bone density talk on obesity drugnews2024-11-13T12:20:55+00:00November 13th, 2024|Endpoints News|
TRexBio raises $84M to take in-house immune program into the clinicnews2024-11-13T12:00:35+00:00November 13th, 2024|Endpoints News|
Exclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bionews2024-11-13T12:00:08+00:00November 13th, 2024|Endpoints News|
BioNTech buys out partner Biotheus for PD-L1/VEGF cancer drugnews2024-11-13T11:45:55+00:00November 13th, 2024|Endpoints News|
Syros’ shares plummet as blood cancer drug fails againnews2024-11-13T11:29:54+00:00November 13th, 2024|Endpoints News|
Pfizer looking to sell hospital drugs unit — reportsnews2024-11-12T21:05:47+00:00November 12th, 2024|Endpoints News|
AstraZeneca CEO reaffirms commitment to China following executive’s detentionnews2024-11-12T20:43:03+00:00November 12th, 2024|Endpoints News|
Syndax’s menin inhibitor succeeds in pivotal trial, but investors aren’t impressednews2024-11-12T20:29:16+00:00November 12th, 2024|Endpoints News|
Merck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosisnews2024-11-12T19:48:28+00:00November 12th, 2024|Endpoints News|
FDA denies Ocaliva full approval, but Intercept hopes to keep drug on marketnews2024-11-12T19:14:56+00:00November 12th, 2024|Endpoints News|
